Reaching out beyond first-line treatments in advanced biliary tract cancers
- PMID: 32569724
- DOI: 10.1016/j.annonc.2020.06.002
Reaching out beyond first-line treatments in advanced biliary tract cancers
Conflict of interest statement
Disclosure AL: Travel and educational support from Ipsen, Pfizer, Bayer, AAA, Sirtex, Novartis, Mylan and Delcath. Speaker honoraria from Merck, Pfizer, Ipsen and Incyte. Advisory honoraria from EISAI, Nutricia, Ipsen, QED and Roche. Member of the Knowledge Network and NETConnect Initiatives funded by Ipsen. JWV: Consulting or Advisory role for Agios, AstraZeneca, Delcath Systems, Keocyt, Genoscience Pharma, Incyte, Ipsen, Merck, Mundipharma EDO, Novartis, PCI Biotech, Pfizer, Pieris Pharmaceuticals, QED and Wren Laboratories; Speakers' Bureau for Imaging Equipment Limited, Ipsen, Novartis, NuCana; and Travel Grants from Celgene and NuCana.
Comment on
-
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.Ann Oncol. 2020 Sep;31(9):1169-1177. doi: 10.1016/j.annonc.2020.05.018. Epub 2020 May 25. Ann Oncol. 2020. PMID: 32464280 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
